Advertisement

Medical Oncology

, 32:87 | Cite as

GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway

  • Zhongyong Wang
  • Hui Yuan
  • Chao Sun
  • Liang Xu
  • Yanming Chen
  • Qing Zhu
  • Haifeng Zhao
  • Qiang Huang
  • Jun DongEmail author
  • Qing LanEmail author
Original Paper

Abstract

Among the gliomas, glioblastoma (GBM) is the highest grade and the most malignant glioma tumor. GATA2 is a hematopoietic factor that has been intensely studied in hematopoietic malignancies. Recently, the functions of GATA2 as an oncogene in other types of human cancer have been reported. However, no role for GATA2 in the development and progression of glioma has been reported to date. In the present study, we found that the expression level of GATA2 is upregulated in GBM and is correlated with GBM outcome. Ectopic expression of GATA2 or RNAi-mediated knockdown of GATA2 significantly enhanced or inhibited proliferation, migration and invasion of glioma cells. Moreover, we found that epidermal growth factor receptor and extracellular signal-regulated kinase, as upstream components of the signaling pathway, upregulate GATA2 expression; moreover, GATA2 promotes Elk-1 expression. Therefore, a genetic approach or pharmacological intervention targeting GATA2 could potentially serve as an effective strategy for treating glioma patients.

Keywords

GATA2 Glioma Glioblastoma EGFR ERK 

Notes

Acknowledgments

This work was supported by University Graduate Students’ Scientific Research Innovative Program of Jiangsu Province, China (CXLX12-0843); National Natural Science Foundation of China (81172400, 81272799 and 81472739); Scientific and Technological Development Program of Suzhou, China (SYS201477, SYSD2012090); and Priority Academic Program Development of Jiangsu Higher Education Institutions, China.

Conflict of interest

None.

References

  1. 1.
    Ahluwalia MS, Chang SM. Medical therapy of gliomas. J Neurooncol. 2014;119:503–12.CrossRefPubMedGoogle Scholar
  2. 2.
    Prosniak M, Harshyne LA, Andrews DW, Kenyon LC, Bedelbaeva K, Apanasovich TV, Heber-Katz E, Curtis MT, Cotzia P, Hooper DC. Glioma grade is associated with the accumulation and activity of cells bearing M2 monocyte markers. Clin Cancer Res. 2013;19:3776–86.CrossRefPubMedGoogle Scholar
  3. 3.
    Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL. Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomark Prev. 2014;23:1985–96.CrossRefGoogle Scholar
  4. 4.
    Martinez R, Schackert G, Yaya-Tur R, Rojas-Marcos I, Herman JG, Esteller M. Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme. J Neurooncol. 2007;83:91–3.CrossRefPubMedGoogle Scholar
  5. 5.
    Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG 2nd, Aldape K. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res. 2001;61:1122–8.PubMedGoogle Scholar
  6. 6.
    Zheng R, Blobel GA. GATA transcription factors and cancer. Genes Cancer. 2010;1:1178–88.CrossRefPubMedCentralPubMedGoogle Scholar
  7. 7.
    Bresnick EH, Katsumura KR, Lee HY, Johnson KD, Perkins AS. Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies. Nucleic Acids Res. 2012;40:5819–31.CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Chlon TM, Crispino JD. Combinatorial regulation of tissue specification by GATA and FOG factors. Development. 2012;139:3905–16.CrossRefPubMedCentralPubMedGoogle Scholar
  9. 9.
    Vicente C, Conchillo A, García-Sánchez MA, Odero MD. The role of the GATA2 transcription factor in normal and malignant hematopoiesis. Crit Rev Oncol Hematol. 2012;82:1–17.CrossRefPubMedGoogle Scholar
  10. 10.
    Wang Y, He X, Ngeow J, Eng C. GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum Mol Genet. 2012;21:569–76.CrossRefPubMedGoogle Scholar
  11. 11.
    Kumar MS, Hancock DC, Molina-Arcas M, Steckel M, East P, Diefenbacher M, Armenteros-Monterroso E, Lassailly F, Matthews N, Nye E, Stamp G, Behrens A, Downward J. The GATA2 transcriptional network is requisite for RAS oncogene-driven non-small cell lung cancer. Cell. 2012;149:642–55.CrossRefPubMedGoogle Scholar
  12. 12.
    Chiang YT, Wang K, Fazli L, Qi RZ, Gleave ME, Collins CC, Gout PW, Wang Y. GATA2 as a potential metastasis-driving gene in prostate cancer. Oncotarget. 2014;5:451–61.PubMedCentralPubMedGoogle Scholar
  13. 13.
    Kancha RK, von Bubnoff N, Peschel C, Duyster J. Functional analysis of epidermal growth factor receptor (EGFR) mutations and potential implications for EGFR targeted therapy. Clin Cancer Res. 2009;15:460–7.CrossRefPubMedGoogle Scholar
  14. 14.
    Liu KJ, Chen CT, Hu WS, Hung YM, Hsu CY, Chuang BF, Juang SH. Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme. Int J Oncol. 2004;24:581–90.PubMedGoogle Scholar
  15. 15.
    Carlsson J, Ren ZP, Wester K, Sundberg AL, Heldin NE, Hesselager G, Persson M, Gedda L, Tolmachev V, Lundqvist H, Blomquist E, Nistér M. Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression. J Neurooncol. 2006;77:33–45.CrossRefPubMedGoogle Scholar
  16. 16.
    Chen A, Xu J, Johnson AC. Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1. Oncogene. 2006;25:278–87.PubMedGoogle Scholar
  17. 17.
    Mut M, Lule S, Demir O, Kurnaz IA, Vural I. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3 K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells. Int J Biochem Cell Biol. 2012;44:302–10.CrossRefPubMedGoogle Scholar
  18. 18.
    Wu P, Wee P, Jiang J, Chen X, Wang Z. Differential regulation of transcription factors by location-specific EGF receptor signaling via a spatio-temporal interplay of ERK activation. PLoS ONE. 2012;7:e41354.CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Menon LG, Pratt J, Yang HW, Black PM, Sorensen GA, Carroll RS. Imaging of human mesenchymal stromal cells: homing to human brain tumors. J Neurooncol. 2012;107:257–67.CrossRefPubMedGoogle Scholar
  20. 20.
    Terasaki M, Sugita Y, Arakawa F, Okada Y, Ohshima K, Shigemori M. CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target. Brain Tumor Pathol. 2011;28:89–97.CrossRefPubMedGoogle Scholar
  21. 21.
    Broniscer A, Baker SJ, Stewart CF, Merchant TE, Laningham FH, Schaiquevich P, Kocak M, Morris EB, Endersby R, Ellison DW, Gajjar A. Phase I and pharmacokinetic studies of erlotinib administered concurrently with radiotherapy for children, adolescents, and young adults with high-grade glioma. Clin Cancer Res. 2009;15:701–7.CrossRefPubMedCentralPubMedGoogle Scholar
  22. 22.
    Ménard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E. Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004;61:2965–78.CrossRefPubMedGoogle Scholar
  23. 23.
    Adachi T, Kar S, Wang M, Carr BI. Transient and sustained ERK phosphorylation and nuclear translocation in growth control. J Cell Physiol. 2002;192:151–9.CrossRefPubMedGoogle Scholar
  24. 24.
    Labussière M, Boisselier B, Mokhtari K, Di Stefano AL, Rahimian A, Rossetto M, Ciccarino P, Saulnier O, Paterra R, Marie Y, Finocchiaro G, Sanson M. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Neurology. 2014;83:1200–6.CrossRefPubMedGoogle Scholar
  25. 25.
    Taylor TE, Furnari FB, Cavenee WK. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. Curr Cancer Drug Targets. 2012;12:197–209.CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Moriguchi T, Yamamoto M. A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation. Int J Hematol. 2014;100:417–24.CrossRefPubMedGoogle Scholar
  27. 27.
    Goncharenko-Khaider N, Matte I, Lane D, Rancourt C, Piché A. Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis. Mol Cancer. 2012;11:84.CrossRefPubMedCentralPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Zhongyong Wang
    • 1
  • Hui Yuan
    • 2
  • Chao Sun
    • 1
  • Liang Xu
    • 1
  • Yanming Chen
    • 1
  • Qing Zhu
    • 1
  • Haifeng Zhao
    • 3
  • Qiang Huang
    • 1
  • Jun Dong
    • 1
    Email author
  • Qing Lan
    • 1
    Email author
  1. 1.Department of NeurosurgerySecond Affiliated Hospital of Soochow UniversitySuzhouChina
  2. 2.Department of OtorhinolaryngologySecond Affiliated Hospital of Soochow UniversitySuzhouChina
  3. 3.Department of PathologySecond Affiliated Hospital of Soochow UniversitySuzhouChina

Personalised recommendations